Transparency in Europe: A Quantitative Study.

Area of Science:

• Pharmacovigilance and Regulatory Science
• Health Communication
• Public Health Policy

Background:

• European pharmaceutical regulators are increasing transparency by providing public access to clinical trial data.
• This policy shift aims to improve risk-benefit communication for patients.
• A systematic review of these new transparency policies is needed.

Purpose of the Study:

• To explore the effects of new transparency policies on patient and public reactions.
• To assess how European citizens respond to regulators' increased data access.
• To inform evidence-based transparency policies integrating benefit-risk communication.

Main Methods:

• A cross-national European survey was conducted.
• The survey included 5,648 respondents from Great Britain, the Netherlands, Spain, France, Germany, and Sweden.
• Data were analyzed to understand public reactions to transparency initiatives.

Main Results:

• Significant national variations exist in how European citizens react to transparency policies.
• Public reactions are influenced by cultural and societal factors across different European countries.
• The study highlights the need for tailored communication strategies.

Conclusions:

• Transparency policies require evidence-based development, considering national differences.
• Effective benefit-risk communication is crucial for public trust and understanding.
• Six recommendations are proposed to enhance the European transparency model in health and safety domains.